JAMESTOWN — The New York State Office of Addiction Services and Supports (OASAS) has announced the award of capital funding to establish a new 100-slot Opioid Treatment Program in Chautauqua County.

The new program will be operated by UPMC Chautauqua at WCA and located at the Jones Memorial Health Center in Jamestown. The project was awarded through a Request for Proposals process administered by OASAS. This will be the first OTP program located in Chautauqua County.

“Funding for this new treatment program builds on targeted investments across the state as part of our aggressive efforts to combat the opioid epidemic,” said Lt. Gov. Kathy Hochul, co-chair of the state Heroin and Opioid Task Force. “The Opioid Treatment Program in Jamestown will add 100 treatment slots to help individuals and families on the road to recovery in Chautauqua County. We are committed to advancing our efforts to fight this crisis by expanding treatment and support services to help save lives.”

“Accessing the right type of treatment is vital for people affected by substance use disorders,” OASAS Commissioner Arlene Gonzalez-Sanchez said. “By establishing the first OTP program in Chautauqua County, more people in Western New York will be able to receive these vital services closer to where they live and begin their life in long-term recovery.”

Opiod Treatment Programs provide medication assisted treatment in combination with counseling and behavioral therapies for those suffering from addiction. This approach allows for a patient-centered, individualized treatment of substance use. Research shows that when treating substance use disorders, a combination of medication and behavioral therapies is most successful.

The new OTP will add to the existing substance use disorder services already in place at the Jones Memorial Health Center, which include an outpatient program and a residential treatment program. The new OTP will enable UPMC Chautauqua at WCA to provide all three FDA-approved medicines for addiction (methadone, buprenorphine, and vivitrol). The exact amount of capital funding for this facility will be determined following a feasibility study conducted by UPMC and OASAS.

The facility is located at 51 Glasgow Ave.